Abstract
Retraction of ‘Astragaloside IV (AS-IV) alleviates the malignant biological behavior of hepatocellular carcinoma via Wnt/β-catenin signaling pathway’ by ZhongYu Jiang et al., RSC Adv., 2019, 9, 35473–35482, https://doi.org/10.1039/C9RA05933D.
The Royal Society of Chemistry hereby wholly retracts this RSC Advances article due to concerns with the reliability of the data in the published article.
The panels labelled ‘AIV 50 noml/l/Hep3B’ and ‘AIV 100 noml/l/Hep3B’ in Fig. 3b are duplicated in another publication by different authors (R. Sun, R. Zhai, C. Ma and W. Miao, Cancer Med., 2020, 9, 1141–1151).
Many panels in Fig. 4c have been duplicated in other publications by different authors (W. Xiao, Y. Liu, M. Dia, Y. Li, R. Peng, S. Yu and H. Liu, Inter. Jour. Mol. Med., 2020, 46, 700–708; T. Liu, A. Li, Y. Xu and Y. Xin, Cancer Med., 2019, 8, 751–760; and X. Wang, Y. Chang, M. Gao and F. Zhang, Onco. Targets Ther., 2020, 13, 10097–10109).
The ‘AIV (50 mg kg−1)/VEGF panel in Fig. 6c is duplicated in another publication by different authors (N. Li, C. Cheng and T. Wang, Onco. Targets Ther., 2020, 21, 4495–4505).
The authors were asked to provide the raw data for this article, but did not respond. Given the significance of the concerns about the validity of the data, and the lack of raw data, the findings in this paper are not reliable.
The authors have been informed but have not responded to any correspondence regarding the retraction.
Signed: Laura Fisher, Executive Editor, RSC Advances
Date: 17/04/2024